Antibody Drug Conjugates Market Size, Share & Trends Report

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable, Non-cleavable), By Product, By Target, By Region, And Segment Forecasts, 2024 - 2030

  • Report ID: GVR-2-68038-741-4
  • Number of Report Pages: 125
  • Format: PDF, Horizon Databook
  • Historical Range: 2018 - 2023
  • Forecast Period: 2024 - 2030 
  • Industry: Healthcare

Research Methodology

A three-pronged approach was followed for deducing the antibody drug conjugates market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:

Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for antibody drug conjugates market to gather the most reliable and current information possible.

  • We buy access to paid databases such as Hoover’s and Factiva for company financials, industry information, white papers, industry journals, SME journals, and more.
  • We tap into Grand View’s proprietary database of data points and insights from active and archived monitoring and reporting.
  • We conduct primary research with industry experts through questionnaires and one-on-one phone interviews.
  • We pull from reliable secondary sources such as white papers and government statistics published by organizations like WHO, NGOs, World Bank, etc., Key Opinion Leaders (KoL) publications, company filings, investor documents, and more.
  • We purchase and review investor analyst reports, broker reports, academic commentary, government quotes, and wealth management publications for insightful third-party perspectives.

Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of antibody drug conjugates market data depending on the type of information we’re trying to uncover in our research.

  • Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.

  • Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.

  • Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.

  • Qualitative Functional Deployment (QFD) Modelling for market share assessment.

Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.

  • Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.

  • Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.

  • This step also entails the finalization of the report scope and data representation pattern.

  • Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.

Antibody Drug Conjugates Market Categorization:

The antibody drug conjugates market was categorized into three segments, namely application (Blood Cancer, Breast Cancer, Urothelial Cancer & Bladder Cancer), technology (Technology type, Linker technology type, Payload technology), and regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)

Segment Market Methodology:

The antibody drug conjugates market was segmented into application, technology, and regions. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:

Market research approaches: Bottom-up

  • Demand estimation of each product across countries/regions summed up to from the total market.

  • Variable analysis for demand forecast.

  • Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.

  • Primary interviews for data revalidation and insight collection.

Market research approaches: Top-down

  • Used extensively for new product forecasting or analyzing penetration levels.

  • Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.

  • Primary interviews and vendor-based primary research for variable impact analysis.

Market research approaches: Combined

  • This is the most common method. We apply concepts from both the top-down and bottom-up approaches to arrive at a viable conclusion.

Regional Market Methodology:

The antibody drug conjugates market was analyzed at a regional level. The globe was divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, keeping in focus variables like consumption patterns, export-import regulations, consumer expectations, etc. These regions were further divided into twenty-three countries, namely, the U.S.; Canada; the UK; Germany; France; Spain; Italy; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait

All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.

Antibody Drug Conjugates market companies & financials:

The antibody drug conjugates market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:

  • Takeda Pharmaceutical Company Limited - Takeda Pharmaceutical Company Limited is a global research-based pharmaceutical company. It was established in 1781 and is headquartered in Japan. It is one of the largest pharmaceutical companies in Japan. The company’s six core business areas are cardiovascular & metabolic conditions, oncology, central nervous system diseases, respiratory & immunology, general medicine, and vaccines. Takeda markets its products in about 100 countries worldwide. As of March 2020, the company had 47,495 employees.

  • F. Hoffmann-La Roche Ltd. - F. Hoffmann-La Roche Ltd. operates through two divisions: pharmaceuticals and diagnostics. It was established in 1896 and is headquartered in Switzerland. Its pharmaceuticals division focuses on therapy areas such as oncology, infectious diseases, ophthalmology, immunology, and neuroscience. In addition, it is a leading provider of anticancer therapeutics. As of December 2020, the company had 101,465 employees. The company has a presence in over 150 countries, and its main subsidiaries include Genentech, Inc.; Chugai Pharmaceutical Co., Ltd.; Flatiron Health, Inc.; Ventana Medical Systems, Inc.; and mySugr GmbH.

  • Pfizer, Inc. - Pfizer, Inc. manufactures and offers products to treat a wide range of diseases, including diabetes, immunological conditions, cardiac disorders, cancers, and dermatological disorders. It was established in 1849 and is headquartered in the U.S. It operates through two segments: Innovative Health and Essential Health. The company serves five sectors: primary care, oncology, animal & consumer healthcare, emerging economies, and nutrition. It has 64 manufacturing sites worldwide. In addition, Pfizer has formed strategic alliances with companies such as Johnson & Johnson Services, Inc.; Merck & Co., Inc.; GE Healthcare; Novartis AG; F. Hoffmann-La Roche Ltd.; and Bayer AG to strengthen its market position. As of December 2020, the company had 78,500 employees.

  • AstraZeneca - AstraZeneca is a global pharmaceutical company involved in the research, development, manufacture, and marketing of prescription medicines. The company mainly focuses on oncology, cardiovascular & metabolic diseases, and respiratory therapy. In addition, it is also active in the fields of autoimmunity, neuroscience, and infection. The company is present in more than 100 countries and offers innovative medicines to millions of patients worldwide. In January 2019, AstraZeneca divided its business into two units: oncology and biopharmaceuticals. The company targets biological drivers of cancer in the oncology segment through immuno-oncology, tumor drivers & resistance, DNA damage response, and antibody-drug conjugates. The company’s R&D is concentrated in the European and North American regions.

  • Gilead Sciences, Inc. - Gilead Sciences, Inc. is a U.S-based biopharmaceutical company that manufactures and commercializes drugs, including antiviral products to treat HIV, hepatitis B, hepatitis C, and influenza. Moreover, the company focuses on therapeutic areas such as hepatology, oncology, cardiovascular diseases, and inflammatory & respiratory diseases. The company was founded in 1987, and as of January 2020, it had 11,800 employees.

  • Astellas Pharma - Astellas Pharma is a research-based pharmaceutical company. It was established in 1923 and is headquartered in Japan. It focuses on developing drugs & medical solutions; the company’s core business areas include immunology, urology, cardiology, diabetes, infectious diseases, oncology, gastrointestinal diseases, and diseases of the central nervous system. Its main products include Padcev and Betanis/BETMIGA/Myrbetriq. As of March 2020, it had 15,883 employees.

  • Seagen, Inc. - Seagen, Inc., formerly known as Seattle Genetics, Inc., is a multiproduct biotechnology company that discovers, develops, and commercializes cancer-targeting therapies. It was founded in 1998 and is headquartered in the U.S. Currently, it has three commercialized products: Adcetris, Padcev, and Tukysa. In addition, it is developing a pipeline of innovative medicines for solid tumors and blood malignancies to meet medical needs & improve patient outcomes. As of December 2020, the company had 2,092 employees.

  • Daiichi Sankyo Company, Limited - Daiichi Sankyo Company, Limited. was established in 2005 in Japan through a merger of Daiichi Pharmaceuticals and Sankyo. Daiichi Sankyo delivers innovative products and services in more than 20 countries across the globe. The company develops generic drugs as well as new methods to discover & deliver medicines. It has various therapeutic agents for the acute coronary syndrome (ACS), venous thromboembolism, hypertension, and others. The company’s business includes innovative pharmaceuticals, generics, vaccines, and OTC drugs. It has 51 group companies in the U.S., Germany, France, Italy, Spain, the UK, Netherlands, Thailand, and 24 countries.

  • GlaxoSmithKline Plc - GlaxoSmithKline plc (GSK) is engaged in three areas globally—research, development, and manufacturing of innovative pharmaceutical medicines, vaccines, & consumer healthcare products. The company aims to develop high-quality and differentiated products. The pharmaceutical business consists of a broad portfolio, with commercially available innovative & established medicines for respiratory diseases and HIV/AIDS. The company’s R&D focuses mainly on the immune system and the application of genetics & advanced technologies. It majorly invests in scientific and technical excellence to develop & launch pipeline products that meet the needs of patients, consumers, and payers. The company developed several vaccines and delivered around 2 million vaccine doses per day to people living in 160 countries. It is into the respiratory diseases segment for 40 years and has broadened & strengthened its portfolio by adding new medicines containing ICS, LAMA, & LABA.

  • ADC Therapeutics - ADC Therapeutics is a biotechnology company that focuses on developing ADCs to treat solid and hematological cancers. It was established in 2011 and is headquartered in Switzerland. It is known for Zynlonta, an ADC used for the treatment of relapsed or refractory diffuse large B-cell lymphoma. In addition, the company has several ADC drugs in its product pipeline, such as Loncastuximab tesirine-lpyl, Camidanlumab tesirine, ADCT-602, and ADCT-601.

Value chain-based sizing & forecasting

Supply Side Estimates

  • Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.

  • Segment revenue determination via variable analysis and penetration modeling.

  • Competitive benchmarking to identify market leaders and their collective revenue shares.

  • Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.

Demand side estimates

  • Identifying parent markets and ancillary markets

  • Segment penetration analysis to obtain pertinent

  • revenue/volume

  • Heuristic forecasting with the help of subject matter experts

  • Forecasting via variable analysis

Antibody Drug Conjugates Market Report Objectives:

  • Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.

  • Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.

  • Understanding market estimates and forecasts (with the base year as 2022, historic information from 2018 to 2020, and forecast from 2023 to 2030). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.

Antibody Drug Conjugates Market Report Assumptions:

  • The report provides market value for the base year 2022 and a yearly forecast till 2030 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.

  • The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.

  • We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.

  • All market estimates and forecasts have been validated through primary interviews with the key industry participants.

  • Inflation has not been accounted for to estimate and forecast the market.

  • Numbers may not add up due to rounding off.

  • Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).

  • Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).

  • Latin America includes Central American countries and the South American continent

  • Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.

Primary Research

GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.

We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:

  • Report/Market scope: If the market study is global, we send questionnaires to industry experts across various regions, including North America, Europe, Asia Pacific, Latin America, and MEA.

  • Market Penetration: If the market is driven by technological advancements, population density, disease prevalence, or other factors, we identify experts and send out questionnaires based on region or country dominance.

The time to start receiving responses from industry experts varies based on how niche or well-penetrated the market is. Our reports include a detailed chapter on the KoL opinion section, which helps our clients understand the perspective of experts already in the market space.

What questions do you have? Get quick response from our industry experts. Request a Free Consultation



This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.



We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member


ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon